
Newton Neurolens N3 measurement system has received CE marking under the European Union Medical Device Regulation (EU MDR). The certification clears the technology for commercialization in the European Union and European Economic Area and expansion into European markets.
Newton currently offers its products in the United States and Canada. The company says its planned European rollout in 2027 will mark its expansion into additional international markets with more countries to follow.
“CE marking under the MDR is a defining milestone for Newton,” says Davis Corley, CEO of Newton. “It reflects the rigor behind our technology and our team, and it opens the door for eye care professionals across Europe to offer their patients a new answer to symptoms they’ve often lived with for years.”
Ocular Alignment Measurement
The N3 system uses eye-tracking technology that captures how the eyes align and work together to measure ocular alignment at near and distance. The measurements provide data for prescribing Neurolens with Contoured Prism technology, which is designed to relieve symptoms associated with ocular misalignment, including headaches, neck and shoulder pain, and motion sickness.
The headset-based system creates a controlled testing environment and is designed for use in pretesting areas. According to Newton, trained staff can administer the automated test in a few minutes, with results providing Neurolens prescription-ready measurements.
Clinical Evidence
According to the company, more than 4 million eye alignment measurements have been completed using Neurolens technology, which has also helped more than 350,000 patients across North America.
In a clinical trial published in Translational Vision Science & Technology in 2024, patients experienced an average five-point reduction in Headache Impact Test-6 (HIT-6) scores after four weeks of Neurolens wear. HIT-6 measures the impact of headaches on daily life.
Newton also reports that 90% of Neurolens wearers responding to a survey after 60 days reported improvement in symptoms.

